Biocryst Pharmaceuticals (BCRX) Other Non Operating Income (2011 - 2026)

Biocryst Pharmaceuticals (BCRX) has 16 years of Other Non Operating Income data on file, last reported at -$1.5 million in Q1 2026.

• Quarterly Other Non Operating Income fell 146300.0% year-over-year to -$1.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$16.0 million (down 30905.77% YoY) and the FY2025 annual result came in at -$17.3 million, changed N/A from the prior year.
• Other Non Operating Income improved to -$1.5 million in Q1 2026, from -$10.4 million in the prior quarter.
• In the past five years, Other Non Operating Income ranged from a high of $28.0 million in Q4 2023 to a low of -$29.0 million in Q2 2023.
• A 5-year average of -$1.2 million and a median of -$130500.0 in 2022 frame the typical range for Other Non Operating Income.
• Annual changes were most pronounced in 2023 — Other Non Operating Income surged 1510.99% — and 2026, when it slumped 146300.0%.
• Tracing BCRX's Other Non Operating Income over 5 years: stood at -$2.0 million in 2022, then surged by 1510.99% to $28.0 million in 2023, then sank by 99.87% to $37000.0 in 2024, then plunged by 28264.86% to -$10.4 million in 2025, then soared by 85.97% to -$1.5 million in 2026.
• The last three Other Non Operating Income figures came in at -$1.5 million (Q1 2026), -$10.4 million (Q4 2025), and $35000.0 (Q3 2025), per Business Quant data.